Metals in our minds: therapeutic implications for neurodegenerative disorders (Q35811065)

10 August 2017

1 reference

title

Metals in our minds: therapeutic implications for neurodegenerative disorders (English)

1 reference

10 August 2017

1 reference

P Murali Doraiswamy

1 reference

10 August 2017

Anne E Finefrock

series ordinal

1 reference

10 August 2017

publication date

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

431-434

1 reference

The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Current status of metals as therapeutic targets in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Current status of antioxidant therapy for Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Iron and Parkinson's Disease: Chelators to the Rescue?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Iron pigment in the brain of a man with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Iron metabolism and mitochondrial abnormalities in Friedreich ataxia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

The metallobiology of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Characterization of Copper Interactions with Alzheimer Amyloid β Peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

In vivo reduction of amyloid-beta by a mutant copper transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Intramuscular desferrioxamine in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Metal chelation as a potential therapy for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Treatment of Alzheimer's disease with clioquinol

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Clioquinol's return: cautions from Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

[Aetiological and clinical study on subacute myelo-optico-neuropathy (SMON) (author's transl)].

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

3-Hydroxykynurenine and 3-Hydroxyanthranilic Acid Generate Hydrogen Peroxide and Promote α-Crystallin Cross-Linking by Metal Ion Reduction†

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Metals and neuroscience.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900809-9

7 January 2021

10.1016/S1474-4422(04)00809-9

Identifiers

DOI

1 reference

10 August 2017

1 reference